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Background: Late-life depression is associated with high rates of morbidity, premature mortality, disability,
functional decline, caregiver burden and increased health care costs. While clinical and public health approaches
are focused on prevention or early intervention strategies, the ideal method of intervention remains unclear.
No study has set out to evaluate the role of neurobiological agents in preventing depressive symptoms in older
populations at risk of depression.
Methods/Design: Subjects with previously reported sub-threshold depressive symptoms, aged 60 to 74 years, will
be screened to participate in a single-centre, double-blind, randomised controlled trial with three parallel groups
involving omega-3 fatty acid supplementation or sertraline hydrochloride, compared with matching placebo.
Subjects will be excluded if they have current depression or suicide ideation; are taking antidepressants or any
supplement containing omega-3 fatty acid; or have a prior history of stroke or other serious cerebrovascular or
cardiovascular disease, neurological disease, significant psychiatric disease (other than depression) or neurodegenerative
disease. The trial will consist of a 12 month treatment phase with follow-up at three months and 12 months to assess
outcome events. At three months, subjects will undergo structural neuroimaging to assess whether treatment effects
on depressive symptoms correlate with brain changes. Additionally, proton spectroscopy techniques will be used to
capture brain-imaging markers of the biological effects of the interventions. The trial will be conducted in urban
New South Wales, Australia, and will recruit a community-based sample of 450 adults. Using intention-to-treat
methods, the primary endpoint is an absence of clinically relevant depression scores at 12 months between the
omega-3 fatty acid and sertraline interventions and the placebo condition.
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Discussion: The current health, social and economic costs of late-life depression make prevention imperative from a
public health perspective. This innovative trial aims to address the long-neglected area of prevention of depression
in older adults. The interventions are targeted to the pathophysiology of disease, and regardless of the effect size of
treatment, the outcomes will offer major scientific advances regarding the neurobiological action of these agents.
The main results are expected to be available in 2017.
Trial Registration: Australian and New Zealand Clinical Trials Registry ACTRN12610000032055 (12 January 2010)
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Depression is one of the most prevalent psychiatric con-
ditions of later life, with clinically relevant depressive
syndromes affecting 9 to 18 % of the general elderly
population [1, 2]. Late-life depression (LLD) describes a
major depressive episode occurring after the age of 60 or
65 years. It is associated with significant morbidity and
mortality, and contributes to cognitive decline [3–5] and
disability [6]. Research suggests that even with optimal
treatment, only 34 % of the LLD disease burden in the
form of ‘years lived with disability’ could be averted [7].
Whilst many older adults fail to meet criteria for major
depression [8], subsyndromal depressive symptoms are
clinically significant and are associated with cognitive
impairment [9] and an increased risk for the development
of major depression [10]. Longitudinal community studies
show that even in those with subsyndromal depression,
persistence or worsening of depressive symptoms occurs
over time [9]. Importantly, both clinical [11] and epi-
demiological [12] studies show that either subsyndromal
or full-threshold depressive disorders are risk factors for
dementia. Even one clinically significant depressive
symptom can increase an individual’s risk of dementia
by up to 20 % [13], and a lifetime episode of depression
increases dementia risk threefold [14]. Importantly,
epidemiological research has shown that a reduction
in major depression (MD) prevalence could reduce
the incidence of Alzheimer’s disease by 7.9 % worldwide
[15], and all cause dementia by up to 10 % [16]. The
current health, social and economic costs of depression
are such that, from a public health perspective, depression
prevention should be seen as imperative, and with the
world’s rapidly ageing population, the development of
effective prevention strategies is now critical.
The need for depression prevention trials
While the need to conduct prevention trials is widely
recognised [9, 10], the ideal method of intervention
is unclear. This may partly reflect the multi-faceted
nature of LLD where lifestyle, behavioural, neurotoxic
(e.g. glucocorticoid), genetic (e.g. via homocysteine), vascu-
lar, glial and inflammatory mechanisms are important
contributors to pathophysiology [17, 18] (see also below).Additionally, it appears that once the illness is established,
neurobiological changes are unlikely to be reversible [17].
Only one known study focusing on ‘at risk’ community
older people has been conducted and utilised a stepped-
care approach (watchful waiting, CBT-based self-help
intervention, problem-solving treatment and referral to a
primary care physician for medication if required). This
study demonstrated a halved incidence of depressive
and anxiety disorders in older adults presenting with
sub-threshold depression and anxiety (not meeting
diagnostic criteria) over a period of 12 months [19], and
these effects were sustained at two years [20]. Recently, in
Phase 1 of the BA trial, we found positive effects of folate
on cognition [21], reinforcing strategies aimed at targeting
underlying pathophysiology.
Mechanisms underpinning brain change in depression
The mechanisms underpinning the link between LLD and
poor longitudinal outcomes are not yet fully delineated,
but a combination of vascular, inflammatory, illness-
specific and neurodegenerative changes may be operative
[22]. In recent years, the role of oxidative stress and
inflammatory mechanisms in depressive disorders has
been the subject of a plethora of studies. Indeed, altered
levels of antioxidants and their synthesising enzymes,
high concentrations of oxidation by-products and
increased pro-oxidant activity levels have been demon-
strated in patients with LLD and have also been linked with
cardiovascular disease [23–31]. Furthermore, increased
inflammatory markers have been demonstrated in patients
with depression and comorbid cognitive impairment, with
chronic inflammation thought to play a central role
in dementia pathophysiology [23, 24, 28–31].
Depressive illness appears to further contribute to brain
change, particularly in the hippocampus, a key structure
involved in memory and neurogenesis. The ‘neurotoxic’
effects of depression may occur via down-regulation of
the hypothalamic-pituitary adrenocortical axis, neurotoxic
effects of glucocorticoids, and reduced expression of
neurotrophins [32]. Indeed, our prior work has shown
direct links between reduced hippocampal size and
impaired memory performance in older people with
depression [33]. Patients with depression have been shown
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factor (BDNF) [32], a key neurotrophin relevant for
hippocampal neurogenesis. The presence of depressive
illness also appears detrimental to the integrity of brain
structures via prolonged hypothalamus-pituitary-adrenal
(HPA) axis activation [13, 14]. Preclinical studies have
demonstrated that prolonged glucocorticoid exposure
resulting from HPA axis hyperactivation may lead to
increased free radical production, reduced glucose
transport, a reduction in brain-derived neurotrophic
factor (for review see [34]) and suppressed neurogenesis.
Together, these effects, resulting from prolonged stress and
hypercortisolaemia, have been posited to account for the
reduction in hippocampal volume commonly associated
with depression occurring across the lifespan [35], and has
been associated with memory decline in older adults
[33, 36]. Thus, in order to reduce the incidence of
LLD and the concomitant cognitive decline, we argue
that prevention should focus on the known underlying
neurobiology including reduction of vascular/inflammatory
risk factors and targeting ‘neuroprotection’ via promotion
of neurotrophic factors [17]. Of relevance to this phase of
our prevention study, the National Heart Foundation
of Australia now recommends omega-3 fatty acid con-
sumption for the prevention of cardiovascular disease,
and a plethora of studies suggest that antidepressants may
offer neuroprotection, the promotion of neurotrophins
and neurogenesis.
Omega-3 for prevention of depression and cognitive
decline
Clinical and epidemiological studies suggest that low levels
of omega-3 fatty acids (specifically eicosapentaenoic acid
(EPA; precursor to DHA), and docosahexaenoic acid
(DHA)) may occur in a number of psychiatric conditions,
including depression. While there have been some negative
findings [37], four controlled intervention studies have
shown that omega-3 fatty acids reduce depressive
symptoms in adults with major depression [38–41].
The size of the effect attributable to omega-3 fatty
acid is unresolved due to the variability in sample size
(20 to 452), measures of depression used and treat-
ment duration (28 to 182 days), as well as the ratios
of EPA and DHA.
With regard to cognitive benefits, longitudinal research
suggests that whole fish consumption is protective against
cognitive decline and dementia [42]. A recent prospective
study, the Singapore Longitudinal Aging Study, showed that
daily omega-3 fatty acid supplements were associated with
lower risk of cognitive decline in a cohort of Chinese adults
aged over 55 years [43]. Positive effects on processing speed
appear to be particularly pronounced. For example, over a
three year time period, higher plasma omega-3 fatty acid
proportions were associated with less decline in cognitivetasks mediated by processing speed [44]. Over a 35-day
period, positive effects of EPA/DHA have been noted in
both mood and reaction time [45].
Despite this body of work focusing on the effects of
omega-3 fatty acid supplementation on depressive symp-
toms and cognition, to date there have been no randomised
controlled trials investigating whether supplementation can
prevent depressive symptoms in older adults. Similarly,
although animal studies show that long-term omega-3 fatty
acid depletion can produce cognitive deficits in normal
animals (for review see [46]), there is still uncertainty
regarding the benefit of omega-3 fatty acid supplementa-
tion on cognitive decline and dementia [47]. However,
given 39 % of Australians aged over 50 years report taking
an omega-3 fatty acid supplement [48], clinical evidence
of a therapeutic benefit from omega-3 fatty acid supple-
mentation in the prevention of cognitive decline warrants
further investigation.
Potential mechanism of effect of omega-3
Omega-3 fatty acids are an integral component of
cell membranes, facilitating membrane fluidity and
permeability. They are necessary for brain function and
development, and may have neuroprotective properties.
Cell signalling and signal transduction, including serotonin
and dopamine pathways, have been shown to be influenced
by omega-3 fatty acids [49]. Omega-3 fatty acids are
essential for the maintenance of cell structure and
have anti-inflammatory effects; mediating and modulating
acute inflammatory responses [50], and decreasing pro-
inflammatory cytokine production [51, 52].
Animal studies have shown that supplementation with
omega-3 fatty acids reversed age-related impairments in
long-term potentiation and depolarization-induced glu-
tamate transmitter release (impairments thought to arise
as a result of a decrease in membrane fluidity). DHA is
decreased in the hippocampus of aged rats and can be
restored through dietary manipulation [53]. In addition,
omega-3 fatty acid has been demonstrated to have a direct
antioxidant effect, with supplementation in ageing rats
shown to enhance antioxidant activity [54]. Importantly, a
novel clinical study using magnetic resonance spectroscopy
(MRS) has demonstrated that in patients with first-episode
psychosis, omega-3 fatty acid supplementation (2 g EPA) is
associated with significant increases in glutathione (GSH),
which is the brain’s major antioxidant in comparison to
treatment as usual [55]. As GSH protects dopaminergic
neurons from oxidative and excitatory damage [56], such
an increase suggests neuroprotective effects.
From a clinical perspective, omega-3 fatty acid supple-
mentation is generally well tolerated, is associated with
few undesirable side effects [41], has limited interaction
with other medications and has been shown to improve
cardiovascular and immune health [41, 57], factors that
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fatty acid supplementation could be a suitable and safe
prevention treatment for depression and cognitive decline
in older adults [46, 58, 59].
Antidepressants for the prevention of depression and
cognitive decline
Evaluation of the role of antidepressants as prevention
agents for depression has seen positive findings in patients
with recurrent major depression [60], post-stroke depres-
sion [61, 62] and diabetes [63]. However there are no
known studies in older ‘at risk’ adults. Due to con-
cerns about the unwanted effects of antidepressants,
psychological interventions have been favoured to date
[20, 19]. However, as it is likely that there are key
bi-directional relationships between depression, cognitive
changes and structural brain changes, the potential neuro-
protective and anti-inflammatory effects of antidepressants,
and sertraline in particular, suggest a role for such treat-
ments not only in the amelioration of depressive and
cognitive symptoms, but also in their prevention. Of added
benefit and significance, a large body of evidence suggests
that antidepressants in older people are associated with
reduced suicide rates [64].
Sertraline as an indicated prevention intervention for
depression
Sertraline, a selective serotonin re-uptake inhibitor (SSRI)
is a specific and potent inhibitor of serotonin re-uptake at
the presynaptic terminal with a modest inhibitory effect
on dopamine reuptake. It has been shown to be effective
in the treatment of major depressive disorder in older
adults, with a dose range of 50-200 mg daily (for review
see [65]), appears to be superior to placebo and has similar
efficacy to other antidepressants (from different classes)
[65]. Additionally, a recent animal study showed that
sertraline has a protective action against cognitive decline
in an induced neurodegenerative disease model [66].
In this study, rats treated with 3-nitropropionic acid
performed poorly on follow-up assessments of memory re-
tention and spatial navigation, whereas those concurrently
treated with sertraline showed a preservation of baseline
function. Due to the lack of anti-cholinergic effects as well
as few interactions with other medications, sertraline is
more tolerable than alternate classes of antidepressant [65].
A number of reviews suggest that sertraline is the most
suitable first choice of antidepressant in patients suffer-
ing major depression due to its balance of efficacy and
acceptability [67].
Potential neuroprotective effects of selective serotonin
re-uptake inhibitors
A growing body of literature suggests that SSRIs
may have both neuroprotective and anti-inflammatoryactions in the brain. Animal studies suggest that SSRIs
may promote the growth of new neuronal pathways
or neurogenesis [68]. Sertraline appears to increase
neuronal differentiation as well as promote neuronal
maturation of human hippocampal progenitor cells
[69]. These effects may be related to the action of
SSRIs to cause up-regulation of BDNF in the hippo-
campus [70]. SSRIs may owe some of their effect to
anti-inflammatory actions on microglia [71]. Indeed
sertraline has been shown to prevent GSH (the brain’s
major antioxidant) reduction in rats with induced
neurodegeneration [66], which is of particular signifi-
cance given recent work showing that this antioxidant
is linked to cognitive decline in older adults at risk of
dementia [72].
Summary and rationale for the second Beyond Ageing
Project randomised controlled trial
Taken together, there is urgent need to conduct relevant
prevention or early intervention trials for depression and
cognitive decline in older adults, and substantial evidence
indicates that omega-3 fatty acid supplementation and
sertraline treatment may have therapeutic potential in
this regard. As we are testing two novel pharmacological
prevention treatments, the comparator of choice will be a
placebo condition.
As such, we aim to conduct a selective prevention trial
for depressive symptoms in an established and well-
characterised cohort of older ‘at risk’ adults, who initially
participated in the first Beyond Ageing Project (BAP)
[73]. The BAP Cohort is a community-based population
of older adults initially aged 60 to 74 years when recruited
in 2005 to 2006 from the Australian Electoral roll. At that
time, participants were recruited from urban and rural
sites in New South Wales and the Australian Capital
Territory, Australia, by postal mail, using address and age-
range information provided by the Australian Electoral
Commission. Given that voting is compulsory in Australia,
this strategy provided for representative population
sampling. Initially, these people were selected as being
at elevated risk of major depression as evidenced by
scores >15 on the Kessler-10 (K-10) questionnaire. The
K-10 questionnaire is a self-report global measure of
psychological distress and comprises ten items con-
cerning anxiety and depressive symptoms experienced
during the most recent 4-week period [74]. The K-10 is
designed for use in community samples, and is useful
for detecting levels of distress that are associated with
independent diagnostic measures (for example, DSM-IV)
in older adults [74]. A K-10 score >15 (moderate psy-
chological distress) is found in 25 % of the aged
population in Australia [75] across all age groups, and
correlates with a 9.1 % 12 month prevalence of affective
disorder.
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ported by longitudinal community studies that have
demonstrated that for older people with subsyndromal
depression, persistence or worsening of symptoms occurs
over time [9]. Additionally, because people with depres-
sive symptoms are prevalent in the community, selective
prevention approaches are feasible. Our approach to
target those ‘at risk’ of depression makes efficient use
of resources since cohorts of subjects with subsyndromal
depression yield the highest attributable risk, the lowest
numbers needed to treat and the shortest time frames for
testing for beneficial effects.
Our prior randomised controlled trial (RCT) with
this BAP cohort showed that mental health literacy
was associated with a decrease in depressive symptoms
and that folate supplementation was associated with
lowered rates of cognitive decline [73]. Here, we extend
our prior work, and propose to evaluate the role of agents
that target inflammation/oxidative stress, vascular health
and neuroprotection.
Objectives
The study aims to determine whether the following
statements are true:
1. Omega-3 fatty acid or sertraline is associated with
reduced rates of depressive symptoms or incident
depression over a 12 month period;
2. Omega-3 fatty acid or sertraline is associated with
reduced rates of cognitive decline over a 12 month
period;
3. Markers of neuronal, glial and inflammatory
brain changes predict an individual’s capacity to
benefit from the omega-3 fatty acid or sertraline
interventions; and,
4. Omega-3 fatty acid or sertraline is associated
with specific changes in brain metabolism in-vivo
as measured by Magnetic Resonance Spectroscopy
(MRS).
Hypotheses
Our hypotheses are as follows:
1. In comparison to placebo, participants receiving
omega-3 fatty acids or sertraline will demonstrate
reduced rates of depressive symptoms and reduced
occurrence of depressive disorder at 12 months;
2. In comparison to placebo, participants
receiving omega-3 fatty acids or sertraline will
have less cognitive decline over 12 months in
the domains of processing speed and memory,
respectively;
3. Evidence of brain compromise (volumetric loss
and/or changes in neurometabolites) will beassociated with reduced efficacy of omega-3 fatty
acid supplementation or sertraline for preventing
depressive symptoms or cognitive decline; and,
4. Participants receiving omega-3 fatty acid and
sertraline supplementation will demonstrate
changes in inflammatory/oxidative stress markers
(GSH) and neuronal integrity (Nacetylaspartate,
NAA) as measured in vivo by MRS.Methods/Design
Trial design
The study is a single-centre, double-blind RCT with
three parallel groups involving two novel pharmaco-
logical treatments and a placebo condition. There will
be three principal occasions of measurement over the
12 month treatment period: baseline, three months,
and 12 months with the primary endpoint an absence
of clinically relevant depressive symptoms at 12 months.
Participants in all three arms will have a brief clinical
review and collect investigational products monthly
for the first three months. They will be contacted via
telephone at the following intervals (one, two, six,
and ten weeks and then monthly to 12 months) for
safety monitoring and adherence purposes. The trial has
been registered on the Australian and New Zealand
Clinical Trial Registry (ACTRN12610000032055). An
additional file depicts the trial design graphically (refer to
Additional file 1).Study setting
The target population for the second BAP clinical trial is
Australian adults, male and female, aged 60 years and
over, with self-reported history of moderate depressive
symptoms. Participants will initially be recruited from
the larger BAP cohort using a computer algorithm to
identify individuals that meet eligibility criteria. For the
second BAP trial, all cohort participants residing in the
greater Sydney metropolitan area with an elevated risk
of major depression (as evidenced by scores ranging
from 16 to 29 on the K-10 at the point of screening for
the first BAP trial), will be invited to participate. Given
the need to attend for face-to-face clinical assessments it
is not feasible to include members of the cohort that
reside outside of the Sydney metropolitan area. Of the
24,352 participants in the cohort database, approximately
4,400 showed sub-threshold depressive symptoms previ-
ously and approximately 60 % of this subgroup were based
in the greater Sydney metropolitan area. Enrichment
strategies will be implemented through the Australian
Electoral Commission, as per our previous methods, should
our recruitment projections be inaccurate. Individuals
will be required to provide informed consent prior to study
participation.
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Participants eligible for the second BAP clinical trial must
comply with all of the following criteria at the point of
randomisation:
1. Have provided written informed consent before any
trial procedures are undertaken,
2. Be aged 60 years or older, and
3. Have a lifetime history of depressive symptoms
(defined as a K-10 score ranging from 16 to 29),
meaning that participants included in the trial will
be at greater risk of depression.
Participants will be excluded from participating in the
second BAP trial if at the point of randomisation they:
1. Have a prior history of stroke or other serious
cerebrovascular or cardiovascular disease, neurological
disease, significant psychiatric disease (other than
major depression) or neurodegenerative disease;
2. Demonstrate clinically significant current depressive
symptoms (as defined by a summed PRIME-MD
Patient Health Questionnaire (PHQ-9) score of ≥10,
which includes a score of ‘2’ or ‘3’ on the 0 to 3 Likert
scale on one and/or both of the cardinal depression
symptoms on the PHQ-9 (that is, question 1 and/or
question 2)) at the time of eligibility screening;
3. Receive a diagnosis of current major depression
based on the psychiatric structured diagnostic
interview conducted during the baseline medical
assessment;
4. Demonstrate suicidal ideation (as defined by a
response of either ‘2’ or ‘3’ on the 0-3 Likert scale at
question nine of the PHQ-9) at the time of eligibility
screening or as determined during the psychiatric
structured diagnostic interview conducted during the
baseline medical assessment;
5. Are currently taking antidepressant medication or any
supplement containing omega-3 fatty acids, or any
other medications that are contraindicated with either
of the pharmacological treatments under study.
Interventions
All eligible participants will be randomised on a 1:1:1
basis to either one of the two novel pharmacotherapy
treatment arms (each with a placebo counterpart) or to
the placebo arm. As such, all participants will take two
types of trial treatments over the course of the treatment
period (that is, either one active and one placebo, or
both placebo variants) as follows:
1. Omega-3 fatty acid intervention, 1,200 mg EPA and
800 mg DHA daily: This dosage combination has
been designed to be consistent with our previouswork using magnetic resonance imaging (MRI) [55]
and is also aligned with a number of other findings
in this area [38, 40] as well as the National Heart
Foundation of Australia Guidelines [76]. This dose
and combination of EPA and DHA is also associated
with a minimal side-effect profile [77]. Participants
in this intervention arm will take four deodorised
omega-3 fatty acid capsules each day and one
microcrystalline cellulose placebo capsule each
morning.
2. Sertraline intervention, 50 mg daily: This is the
recommended intervention for treatment of mild to
moderate depression [78]. The dose was selected to
lessen potential adverse effects as well as for ease of
administration [65, 67]. For the purposes of the trial,
sertraline tablets will be encapsulated and
microcrystalline cellulose will be added to the
capsule to prevent the tablet from rattling within.
Participants will take one encapsulated sertraline
tablet each morning, as well as four paraffin oil
placebo capsules each day.
3. Placebo intervention, daily: Participants in the
control arm will take four paraffin oil placebo
capsules each day and one microcrystalline cellulose
placebo capsule each morning. For the purposes of
the trial, the paraffin oil capsules will be
manufactured to look identical in appearance and
weight to their active omega-3 fatty acid counterparts.
The paraffin oil capsules will also contain small
amount (not more than 5 mg) each of EPA and DHA
to ensure a consistent flavour and smell between the
active and placebo counterparts. The microcrystalline
cellulose placebo capsule will be manufactured to
look identical in appearance and weight to the active
sertraline counterpart.
All randomised participants will receive the capsules
according to the same monthly schedule, irrespective of
the intervention arm assigned. They will be provided at
face-to-face interview each month for the first three
months and then mailed in special packaging to partici-
pants’ homes in three monthly instalments subsequently
thereafter. Participants will self-administer four oil capsules
(either fish oil or paraffin oil) at any time of the day, and
one capsule (either sertraline or microcrystalline cellulose)
in the morning with or without food. Participants will be
given instructions for administration of all study interven-
tions that will include safety information. Participants will
also receive a medication-tracking calendar to aid compli-
ance and recording of any side effects.
Compliance and safety monitoring will be conducted by
telephone assessment (as indicated in Fig. 1) and at
each scheduled clinical review and follow-up assess-
ment. Compliance will also be assessed by capsule count.
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Fig. 1 Flow of Participants
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tracking calendar, along with any unused capsules at each
face-to-face visit where a member of the BAP trial team
will record the number of capsules remaining. In addition,
all participants will undergo blood testing at baseline, 3
months and 12 months whereupon the amount of fatty
acids in the sample will be assessed for the purpose of
compliance.
As this is a prevention study, there is no minimum
response level. Therefore, the assigned study intervention
will not be modified by the trial investigators in any way,
unless the participant and/or the BAP Trial Clinician
recommend discontinuation on the basis of side effects orharms, or the participant withdraws his/her consent. Where
a participant discontinues his/her assigned intervention, all
efforts will be made to retain the participant in the trial to
enable follow-up data collection and prevent missing data.
During the study, details of current and new concomitant
medications will be recorded. A BAP Trial Clinician will be
consulted to approve study interventions with all said
concomitant medications. Particular attention will be paid
to medications likely to interfere with either sertraline or
omega-3 fatty acid, as detailed in the Investigators’
Brochure. Participants and their GPs will be informed of all
medications contraindicated with sertraline and omega-3
fatty acid supplements upon entry to the trial, and asked to
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medication regimes during the study period.
Outcomes
Primary outcome
The primary outcome is the prevention of depressive symp-
toms over a 12 month period. This will comprise the mean
change in severity of depressive symptoms as measured by
scores on the PHQ-9 from baseline to 12 months. The
PHQ-9 is a nine-item assessment of depressive symptoms,
which provides a summary score ranging from zero to 27.
The PHQ-9 is a reliable and valid measure of depressive
symptoms, which has been widely used in both clinical and
epidemiological studies of people with depressive symptoms
and is sensitive to change [79, 80]. This self-report measure
will be embedded into each of the formal assessments at
baseline, three months and 12 months.
Secondary outcomes
Secondary outcomes will comprise: a) prevention of
depression onset at 12 months; b) reduction in cognitive
decline over 12 months; and c) changes in brain neurome-
tabolites and volume over 3 months.
a) Prevention of depression onset: The prevention
of depression onset will be indicated by the
difference in the proportion of participants in
each intervention arm classed as being
asymptomatic for depression at 12 months.
‘Depression’ will be defined by caseness, as
evidenced by a score ≥10 on the PHQ-9.
b) Reduction in cognitive decline: This outcome will
comprise the mean change in performance between
baseline and 12 months across the domains of
processing speed (Cambridge Neuropsychological
Test Automated Battery (CANTAB) Reaction Time
test [81] and the Trailmaking Test Part A [82]) and
memory (CANTAB Paired Associate Learning test
[81] and the Rey Auditory Verbal Learning Test
(RAVLT) [83]).
c) Brain neurometabolites and volume: This outcome
comprises the change in concentration of key
metabolites in the hippocampus (NAA) and anterior
cingulate (GSH) from baseline to three months
(as measured in vivo using magnetic resonance
spectroscopy (MRS), as well as changes in the
volume of the hippocampus at three months).
Other outcomes
Other outcomes measured at baseline, three months and
12 months include:
a) Other binary depression outcome measures that can
be constructed from the PHQ-9 items including‘clinically significant magnitude of change’ and the
number needed to treat;
b) Executive functioning (the Trailmaking Test Part B
[82], Delis-Kaplan Executive Function System
(DKEFS) Stroop Task [84] and the Controlled Oral
Word Association Test (COWAT) [84]);
c) Anxiety (using the Generalised Anxiety Disorder
Scale, GAD-7 [85]);
d) Sleep quality (using the Pittsburgh Sleep Quality
Index, PSQI [86]); and
e) Disability (using the World Health Organisation
Disability Assessment Scale, WHODAS [87]).
In addition, demographic, health and lifestyle factors
will be described by treatment group at trial entry and
overall at three months and 12 months.
Participant timeline
Participants identified in accordance with the pre-specified
sampling frame (see Table 1) will be contacted by mail and
invited to participate in the second BAP trial. The mailed
recruitment package will contain a letter of invitation, the
Participant Information Statement and Consent Form, an
eligibility-screening questionnaire addressing current
depressive symptoms and a reply-paid envelope to return
the required forms to the Brain & Mind Research Institute.
The Participant Information Statement provides a detailed
description of the BAP trial, the procedures and time
involved in participating, information on the three
treatments groups and randomisation process each
participant will undergo to either one of these groups,
confidentiality information and contact information
for the trial team should potential participants want
further information. In providing consent, participants
will be required to enter their full name and sign and date
the form. An independent witness is also required to sign
and date the form, confirming the potential participant is
acting rationally and voluntarily.
Upon receipt of completed consent forms and eligibility
screening questionnaires, a member of the BAP trial team
will assess the potential participant’s eligibility against the
trial inclusion criteria. Those who do not meet criteria will
receive a letter outlining why they have not been selected
to participate. Any potential participant who is identified
in the eligibility-screening questionnaire as being at risk of
self-harm or currently exhibiting clinically significant
depressive symptoms will be contacted by a BAP Trial
Clinician for referral to clinical services. Those who meet
trial inclusion criteria will be contacted via telephone
where further information about the BAP trial will be
provided and informed consent will be undertaken.
Potential participants will undergo further eligibility
screening, whereby the potential participant’s eligibility will
be assessed against the trial exclusion criteria. Participants
Table 1 Sampling framework to identify potential participants in the Beyond Ageing Project (BAP) cohort
Inclusion Criteria Specification
Age at entry to the BAP cohort Aged ≥60 years
Self-reported sub-threshold depressive symptoms at entry
to the BAP cohort
Where responses to all ten items on the K-10 are summed (where ‘all of the time’ = 5
and ‘none of the time’ = 1) and the summed score ranges from 16 to 29
Resides in Sydney, New South Wales Has a postcode in the range of 1000-1920; 2000-2249, 2555-2574;
or 2740-2786
Does not meet criteria for any of the following Exclusion Criteria:
• Self-reported history of serious cerebrovascular or
cardiovascular illness at entry to the BAP cohort
Doctor’s diagnosis of any of the following problems that are not
presently under control:
• Serious heart problems
• Diabetes
• High blood pressure
• Severe blockage of a lung artery
Severe chest pains that are brought on by physical activity or occur while at rest
Doctor’s diagnosis of stroke
Doctor’s diagnosis of mini-stroke or Transient Ischaemic Attack
Heart problem in the last 12 months that led to a hospital admission, hospital
emergency contact or consultation with a specialist
• Self-reported neurological illness at entry to the BAP cohort Ever had an epileptic fit
Currently have epilepsy
Ever had bleeding in the eye
Ever had a serious head injury that interfered with memory, resulted in
loss of consciousness or caused a blood clot in the brain
• Self-reported psychiatric illness at entry to the BAP cohort Doctor’s diagnosis of bipolar disorder or mania
Summed K-10 score ranging from 30 to 50 (suggesting clinical management
of depression presently required, rather than preventative management)
• Self-reported neurodegenerative disease at entry to the
BAP cohort
Doctor’s diagnosis of dementia or Alzheimer’s disease
• Other self-reported significant illness at entry to the
BAP cohort
Doctor’s diagnosis of brain tumour in the last 12 months
Currently have:
• Cancer
• Alcohol and/or drug abuse
• Kidney disease
• Liver disease
• Anaemia or other blood disease
Cockayne et al. Trials  (2015) 16:247 Page 9 of 16who do not meet criteria, due to a prior history of stroke
or other serious cerebrovascular or cardiovascular disease,
neurological disease, significant psychiatric disease
(other than depression) or neurodegenerative disease,
or due to current antidepressant use or omega-3 fatty
acid supplementation, will be thanked for their time
and will not participate further. Any participant who
is already taking an omega-3 fatty acid supplement
but indicates a willingness to cease the supplement for the
duration of the BAP trial will be instructed to undergo a
washout period of at least eight weeks prior to baseline
assessment and randomisation.
Following telephone screening, all eligible participants
will be invited to attend the Trial Coordinating Centre(Brain & Mind Research Institute) for baseline assessment.
One week prior to attendance, participants will be mailed
a self-report questionnaire, which they will complete in
their own time. The baseline assessment will comprise the
following: self-report questionnaire, medical assessment,
neuropsychological assessment, blood sampling and MRS.
Ongoing participation in the trial will be measured from
this time-point.
Sample size
We will randomly select 2,000 of those meeting trial eligi-
bility criteria from the broader BAP cohort to participate.
Even though this cohort has expressed a willingness to
participate in research, we expect a conservative response
Cockayne et al. Trials  (2015) 16:247 Page 10 of 16rate of 50 % from this initial invitation. Assuming 65 % of
those who provide consent will be eligible to participate,
this leaves a potential sample of 650. Taking into account
a 10 % attrition rate post-randomisation (in accordance
with the first BAP prevention trial), this will provide a final
sample of approximately 585.
We will attempt to recruit a minimum of 450 participants
with 150 per group (135 per group with 10 % attrition) for
the comparison of endpoint depression scores between the
omega-3 fatty acid and sertraline interventions and the
placebo condition. Assuming a correlation of 0.7 between
baseline and endpoint depression measures and constancy
of dispersion, the standard deviation of difference scores
is 0.77 × the standard deviation of the raw scores. In a
two-tailed test of contrasting differences between the two
treatment arms, not relying on pooling error sums with
the third treatment arms with alpha = 0.05 and power
80 %, the forecast number of participants can detect
differences in depression change scores of 0.34 standard
deviations. This equates to approximately 0.25 standard
deviations difference in raw depression scores.
Recruitment
Trial participants will be recruited into the study in a
series of waves over 48 months, a procedure utilised in
the first BAP prevention trial. The entire study is expected
to be complete within five years.
Allocation
The allocation of participants to an intervention arm will
be achieved through a centrally coordinated randomisation
service provided by the National Health and Medical
Research Council (NHMRC) Clinical Trials Centre, which
operates independently of the BAP Trial Coordinating
Centre and all trial personnel in day-to-day contact with
participants. Once informed consent is obtained and a
BAP Trial Clinician has assessed eligibility and made the
decision to enrol a participant, a BAP Research Officer will
telephone the Interactive Voice Response System (IVRS) to
perform the random allocation. Confirmation of each
allocation procedure will be automatically emailed to
the BAP Trial Coordinating Centre.
Sequence generation
The randomisation procedure will be based on variable
length permuted blocks. Eligible participants will be
stratified according to sex and presenting depression
severity (their summed K-10 score on the baseline
self-report questionnaire). The last factor is used to
ensure that the ‘tail’ of participants with higher levels
of symptoms is distributed equally across the three
conditions. Symptom severity will be classified in
accordance with the 2007 National Health Survey
[88], where K-10 total scores were collapsed into fourcategories including (low, scores 10-15; moderate, scores
16-21; high, scores 22-29; and very high, scores 30-50). For
the purposes of stratification, scores ranging from 10-15
will be classified as low, and scores ranging from 16
to 50 as high. The allocation sequences within each
strata will be generated by a NHMRC Clinical Trials
Centre Biostatistician and loaded into the IVRS prior
to trial commencement.
Allocation concealment mechanism
The allocation codes will be documented by the
NHMRC Clinical Trials Centre, not to be provided until
the completion of the trial, unless unblinding is required
in an emergency. The allocation code assigned to any
participant will only be broken by the Chief Investigator
or authorised person if the patient’s safety is at risk and
it is absolutely necessary to ascertain the type of treatment
given. The IVRS incorporates an unblinding service
available 24 h a day that can only be accessed by authorised
persons. Where patient safety is under consideration,
ceasing the trial treatments will be the preferred manage-
ment option in contrast to unblinding.
Blinding (masking)
This is a double-blind clinical trial whereby the study
participants and the clinical investigators/trial monitoring
staff will be unaware of the treatment assignment. Only the
BAP Trial Statistician will have access to unblinded data at
the individual level. However, he will not have any direct
contact with trial participants. Several strategies will be
employed to minimise bias through accidental unblinding.
As the two pharmacological treatments under investiga-
tion are different in appearance, blinding will be ensured
by a double-dummy design. This will involve giving all
participants two formulations: one group will receive
the active omega-3 fatty acid treatment plus a placebo
of the sertraline treatment; a second group will receive the
opposite combination (active sertraline plus a placebo of
the omega-3 fatty acid treatment), while the third group
will receive a placebo version of both omega-3 fatty acid
and sertraline.
Additionally, in order to protect the blinding of both
participants and investigators, the active and placebo
variants of each treatment will appear identical in
appearance and weight to their active counterparts. As
previously described, the paraffin oil capsules will also
contain small amount each of EPA and DHA to ensure a
consistent flavour and smell between the omega-3 fatty
acid and placebo counterparts. The packaging and labelling
of each active and placebo intervention will also be identical
in weight, size and appearance.
Clinical outcomes will be assessed by personnel who
are unaware of the participant’s treatment allocation.
The Trial Coordinator will maintain an unblinding log
Cockayne et al. Trials  (2015) 16:247 Page 11 of 16to record any specific personnel that may be accidentally
(or deliberately) unblinded during the course of the trial,
along with the date, scope and reason for doing so.
The routine collection of blood for the purpose of
safety monitoring and adherence to treatment will be
analysed by a central independent laboratory. In order to
preserve the blinded status of clinical investigators,
summary reports indicating whether a participants results
fall within a pre-specified range will be provided for the
purposes of monitoring safety. Samples collected for the
purpose of adherence monitoring will not be analysed
until the completion of the trial.
Data collection methods
Table 2 provides an overview of the timeframe for
assessment and the measures that are used. All self-report
measures will be collected via hardcopy questionnaires that
will be mailed to participants for completion in their
homes at baseline, three month and 12 month time-points.
Participants will return the completed questionnaires to
the Trial Coordinating Centre.
All clinical (medical, psychiatric and neuropsychological)
measures will be collected using standardised instrumentsTable 2 Complete list of outcome measures and assessments
Recruitment Screening/base
assessment
Week(s): −6 to -2 −2 to 0
Informed consent X
Inclusion/exclusion criteria X
Self-report (includes PHQ-9, K-10, GAD-7,
WHODAS, PSQI)
X












Compliance (fatty acid blood analysis) X




Mail out of medications Months seven and 10 (three
Early termination/trial cessation follow-up
phone call
Within three to five days follo
PHQ-9 Patient Health Questionnaire, K-10 Kessler-10 Psychological Distress Scale, GA
Disability Assessment Scale, PSQI Pittsburgh Sleep Quality Index, CANTAB RT and PA
and Paired Associate Learning Test, RAVLT Rey Auditory Verbal Learning Test, DKEFS
Word Association Test, MRS Magnetic resonance spectroscopy
a One month supply
b Three month supplyby staff trained in the trial protocol and procedures. All
clinical assessments, including MRS and MRI, will be
performed at the Trial Coordinating Centre. Clinicians will
be given a hardcopy case record form (CRF) in which
they will document results. Clinicians will be required to
sign-off on the CRF on completion of the assessment.
All MRS data will be transferred offline for post-
processing immediately following acquisition. Metabolite
concentrations will be determined using the LCModel
software package [89].
Drug dispensing and returns will be documented on
individual hardcopy investigational product accountability
forms. Reasons for exclusion, withdrawal or loss to follow-
up will also be recorded.
Data management
All data will be entered electronically into the master
trial database by suitably qualified staff, supervised by the
Trial Coordinator. Data will be entered into a user-friendly
Filemaker platform, and integrity will be enforced through
a variety of mechanisms, including referential data rules,
valid values, range checks and consistency checks. The




















X X X X X
X X
X X X X X X
X X X X X X
month supply)
wing treatment cessation
D-7 Generalised Anxiety Disorder Scale, WHODAS World Health Organisation
L Cambridge Neuropsychological Test Automated Battery Reaction Time Test
Delis-Kaplan Executive Function System Stroop Task, COWAT Controlled Oral
Cockayne et al. Trials  (2015) 16:247 Page 12 of 16be available when applicable. The master trial database will
be held on a secure server hosted by the Faculty of
Medicine, University of Sydney. The trial database will be
password protected, and only authorised trial personnel
will have access. The database will be maintained in
accordance with University of Sydney ICT policy and
procedures. Upon database lock, data will be exported to a
statistical software package for subsequent analysis.
Statistical methods
Primary outcome analysis will be undertaken on an
intention-to-treat basis. Mixed-model repeated measures
analyses will be used because of the ability of this
approach to include participants with missing data [90].
Characteristics of the participants including sociodemo-
graphics, disability, physical activity, sleep and health
and lifestyle factors will also be described by treatment
group and overall at three and 12 months. Safety criteria
including adverse events, laboratory parameters and with-
drawals will also be analysed. The type one error will be
set at 5 %. Descriptive statistics will include number of
participants (N), mean, standard deviation, minimum and
maximum and, if a non-normal distribution, the median
and first/third quartiles will be reported.
Data monitoring
The accuracy, completeness and progress of data will be
monitored continuously throughout the trial. Each CRF
will have a data checklist attached, on which the assess-
ments completed, drugs dispensed and other information
will be recorded. Any missing information or illegible data
will be queried with the researcher, clinician or interviewer
responsible for its collection. Audits will be undertaken
periodically to ensure that all data relating to informed con-
sent, self-report questionnaires, medical and neuropsycho-
logical assessment, MRS, blood tests and dispensing, are
accounted for. All original CRFs will be stored securely by
trial identification number at the Trial Coordinating Centre.
Following data entry into the master trial database, data will
be randomly checked for accuracy and completeness and
verified against source data. Approximately 5 % of partici-
pants will be specifically monitored.
Safety and event monitoring
An independent Data and Safety Monitoring Committee
will be established to safeguard the patients’ interests
and to evaluate formally on a regular basis whether, for
any reason, they would recommend that the study be
modified or stopped. Two formal interim analyses are
planned in accordance with the Data and Safety Monitoring
Committee Charter. The Trial Management Committee,
the collaborators, the study sponsor and all the project staff,
with the exception of the unblinded statistician, will remain
ignorant of the interim results.Harms
During the course of the study, participants will be assessed
for adverse events (AEs) using pre-specified checklists com-
prising both expected (as per the Investigators’ Brochure)
and unexpected adverse events. Clinician-rated assessments
will be undertaken at the one and two month brief review,
as well as at the three and 12 month follow-up assessment.
In addition, participant self-reports will be completed at
each of the same time-points. In accordance with evi-
dence linking the use of some selective serotonin reuptake
inhibitors such as sertraline, with an increased risk of
hyponatraemia (low sodium concentration in blood) in
elderly populations [91] particularly in the first few weeks
of treatment, all study subjects will undergo electrolyte
testing in the weeks following randomisation. In addition
to these clinical and laboratory measurements, research
assistants conducting safety monitoring and adherence
telephone interviews at one, two, six, and ten weeks
and then monthly to 12 months, will also assess for
the occurrence of adverse events using the participant
self-report checklist.
All AEs (including serious adverse events, or SAEs),
regardless of relatedness to the investigational products,
will be recorded on an adverse event form. Recording
will be completed in a concise manner using standard,
acceptable medical terms. Surgical interventions, which
are planned prior to study enrolment, will not be
considered as AEs. All AEs will be classified and graded in
accordance with the Common Terminology Criteria for
Adverse Events (Cancer Therapy Evaluation Program,
Version 3.0, 2006).
Study sponsorship and organisation
The sponsor of the trial is the University of Sydney. For the
purposes of the trial, EPAX 6000 TG/N (raw omega-3 fatty
acid) will be supplied in-kind by Pathway International Pty
Ltd and manufactured by LIPA Pharmaceuticals. LIPA
Pharmaceuticals will also manufacture the matching
paraffin oil capsules. Setrona™ (sertraline hydrochloride)
tablets will be purchased from the Royal Adelaide
Hospital Department of Pharmacy and encapsulated
by Pharmaceutical Packaging Professionals Pty Ltd.
Pharmaceutical Packaging Professionals will also prepare
the matching microcrystalline cellulose placebo capsules,
and provide packaging and labelling for all of the investi-
gational products. The trial is supported by the Bupa
Health Foundation’s Healthy Ageing initiative, along with
the National Health and Medical Research Council of
Australia, through a project grant awarded to the Brain &
Mind Research Institute. The trial is being coordinated
independently of the funding bodies and suppliers of the
investigational products, by the Brain & Mind Research
Institute, Sydney, Australia and overseen by the Trial
Management Committee.
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The Trial Management Committee and investigator
team will allow independent monitors (for example,
regulatory agencies) to visit the site and facilities where
the trial will take place in order to ensure compliance
with the protocol requirements at regular intervals. The
sponsor may also conduct monitoring at regular intervals,
depending on recruitment the rate, and as arranged
between the investigator team and the sponsor.
Ethical considerations
The trial will be undertaken in compliance with the
World Medical Association Declaration of Helsinki
(revised version of Seoul, 2008), international standards
of Good Clinical Practice and the applicable regulatory
requirements in Australia. The design and implementation
of the trial has been approved by The University of Sydney
Human Research Ethics Committee (Reference Number:
12-2009/12097). All important protocol modifications
will be communicated to the Human Research Ethics
Committee prior to implementation.
Discussion
LLD is associated with significant morbidity and mortality,
and contributes to cognitive decline [4] and disability [6]
that is unlikely to be reversible. Even with optimal treat-
ment of LLD, only 34 % of the disease burden in the form
of ‘years lived with disability’ could be averted [7]. The
current health, social and economic costs of depression
make prevention imperative from a public health perspec-
tive [92]. While effective treatments for depression are
available, as many as 50 % of patients will not achieve
remission with their first treatment [93] and ultimately
20 to 30 % will not achieve full recovery [94]. Those
who do achieve full recovery remain at high risk for
further episodes [1]. Furthermore, epidemiological data has
shown that if depressive symptoms in older people were
averted, the prevalence of dementia could be reduced by
up to 10 % [16]. Therefore, prevention of this disease is of
utmost importance.
This innovative trial aims to address the long-neglected
area of prevention of depression in older adults, and repre-
sents an opportunity to test two novel pharmacological
approaches that are particularly relevant and acceptable to
this ‘at risk’ cohort. The interventions are targeted to the
pathophysiology of LLD, and regardless of the effect size of
the intervention, the outcomes of this study will offer
major scientific advances regarding the neurobiological
action of these agents. Importantly, omega-3 fatty acids are
a low cost and low risk prevention dietary supplement that
are already widely used in the community, but have not
been evaluated for their prevention capacity. As sertraline
is the most widely prescribed antidepressant in general
practice, findings from this trial may be directly translatableto clinical practice. Benefits are expected for depressive
symptoms and cognition, and also for broader psychosocial
functioning. If effective, this intervention could feasibly be
delivered on a larger scale with the potential to result in
significant reductions in the high healthcare utilisation and
costs associated with depression.Trial status
Recruitment to the second BAP trial commenced in
July 2011. Recruitment is currently ongoing, and the last
participant randomised is expected to complete his/her
12-month follow-up in late 2016.Additional file
Additional file 1: Flow of participants. Graphical representation of the
flow of participants through the Beyond Ageing Project Phase 2.Abbreviations
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